We are live on ! Find out more
ARTA

A.R.T. Advisors Portfolio holdings

AUM $1.79M
1-Year Est. Return 57.47%
This Fund
S&P 500
This Quarter Est. Return
+3.19%
1 Year Est. Return
+57.47%
3 Year Est. Return
+81.79%
5 Year Est. Return
+178.88%
10 Year Est. Return
–
AUM
$1.77B
AUM Growth
+$95.6M
Cap. Flow
+$79.9M
Cap. Flow %
4.52%
Top 10 Hldgs %
10.21%
Holding
1,825
New
561
Increased
356
Reduced
388
Closed
510

Top Buys

Rank Stock Value
1
NKE icon
Nike
NKE
+$21.7M
2
HLF icon
Herbalife
HLF
+$20.4M
3
TXRH icon
Texas Roadhouse
TXRH
+$18M
4
BKNG icon
Booking.com
BKNG
+$17.7M
5
LOW icon
Lowe's Companies
LOW
+$15.5M

Top Sells

Rank Stock Value
1
SBUX icon
Starbucks
SBUX
+$14.3M
2
UPS icon
United Parcel Service
UPS
+$10.8M
3
LULU icon
lululemon athletica
LULU
+$9.52M
4
AMZN icon
Amazon
AMZN
+$8.2M
5
GILD icon
Gilead Sciences
GILD
+$7.98M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 23.14%
2 Technology 14.57%
3 Healthcare 11.17%
4 Industrials 9.82%
5 Financials 9.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLSD
1201
DELISTED
Clearside Biomedical
CLSD
$95K 0.01%
+6,549
New +$117K
ARAY icon
1202
Accuray
ARAY
$27.8M
$94K 0.01%
+24,330
New +$98.3K
MUX icon
1203
McEwen Inc
MUX
$982M
$94K 0.01%
+5,386
New +$78.8K
VSTO
1204
DELISTED
Vista Outdoor Inc.
VSTO
$94K 0.01%
10,639
+605
+6% +$5.18K
IFRX icon
1205
InflaRx
IFRX
$245M
$92K 0.01%
29,162
+17,300
+146% +$547K
BLCM
1206
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$92K 0.01%
5,434
+3,910
+257% +$106K
APTX
1207
DELISTED
Aptinyx Inc. Common Stock
APTX
$90K 0.01%
27,000
+3,695
+16% +$13.1K
NBRV
1208
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$90K 0.01%
+148
New +$90.8K
TTNP
1209
DELISTED
Titan Pharmaceuticals
TTNP
$89K 0.01%
116
+72
+164% +$65.8K
BFX
1210
DELISTED
BowFlex Inc.
BFX
$89K 0.01%
40,412
+7,260
+22% +$28.6K
ASC icon
1211
Ardmore Shipping
ASC
$675M
$88K 0.01%
+10,784
New +$75.2K
PDLI
1212
DELISTED
PDL BioPharma, Inc.
PDLI
$87K ﹤0.01%
+27,591
New +$89.5K
AXTI icon
1213
AXT Inc
AXTI
$2.53B
$85K ﹤0.01%
+21,363
New +$100K
AKBA icon
1214
Akebia Therapeutics
AKBA
$335M
$84K ﹤0.01%
+17,353
New +$98.7K
PVLA
1215
Palvella Therapeutics
PVLA
$2.01B
$84K ﹤0.01%
+223
New +$66.5K
IVC
1216
DELISTED
Invacare Corporation
IVC
$84K ﹤0.01%
16,200
-155,419
-91% -$1.01M
TNAV
1217
DELISTED
Telenav Inc.
TNAV
$84K ﹤0.01%
10,452
-1,700
-14% -$11.9K
MRSN
1218
DELISTED
Mersana Therapeutics
MRSN
$83K ﹤0.01%
816
-221
-21% -$26K
ABEO icon
1219
Abeona Therapeutics
ABEO
$341M
$82K ﹤0.01%
+684
New +$115K
CERS icon
1220
Cerus
CERS
$575M
$82K ﹤0.01%
14,584
-27,400
-65% -$151K
DMK
1221
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$80K ﹤0.01%
882
+520
+144% +$63.2K
ABUS icon
1222
Arbutus Biopharma
ABUS
$845M
$74K ﹤0.01%
+35,449
New +$90.7K
TBHC
1223
DELISTED
The Brand House Collective
TBHC
$73K ﹤0.01%
+32,317
New +$152K
ELVT
1224
DELISTED
Elevate Credit, Inc.
ELVT
$73K ﹤0.01%
17,738
-15,715
-47% -$70.1K
JE
1225
DELISTED
Just Energy Group Inc
JE
$73K ﹤0.01%
+514
New +$62K
47 48
49
50 51

Similar funds

MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
FFIM
Founders Fund III Management San Francisco, California $435K AUM
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
CCM
Copernicus Capital Management San Francisco, California $8.26M AUM 37.91% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM

A.R.T. Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, A.R.T. Advisors held 1,825 positions worth $1.77B, up 5.7% from $1.67B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

A.R.T. Advisors deployed $79.9M of net new capital in Q2 2019, opening 561 new positions and adding to 356 existing holdings. Its largest new stake was Nike: 257,500 shares worth $21.6M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 23% of assets, up from 16% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was lululemon athletica, an estimated $9.52M trimmed.

  • A.R.T. Advisors's largest Q2 2019 buy was Nike: 257,500 shares worth $21.6M.
  • A.R.T. Advisors added most to Herbalife in Q2 2019, an estimated $20.4M increase.
  • A.R.T. Advisors's biggest Q2 2019 reduction was lululemon athletica, cutting an estimated $9.52M.
  • A.R.T. Advisors fully exited Starbucks in Q2 2019, selling an estimated $14.3M.
  • A.R.T. Advisors's ten largest holdings make up 10% of its $1.77B portfolio in Q2 2019.
  • A.R.T. Advisors opened 561 new positions and closed 510 in Q2 2019.
  • A.R.T. Advisors's portfolio value rose 5.7% quarter-over-quarter to $1.77B.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.